C‐code for Lilly Oncology Drug
On June 9th, 2016
Eli Lilly and Company announce the assignment of a product‐specific C‐code for Portrazza® (necitumumab) injection. The Centers for Medicare & Medicaid Services (CMS) released the April 2016 Update of the Hospital Outpatient Prospective Payment System (OPPS), which included designation of C9475 for Portrazza with the effective date of April 1, 2016.1
Trade Name
HCPCS Code
Strength
NDC
CMS Long Descriptor
Effective Date
Portrazza
C9475
800 mg/50 mL (16 mg/mL)
00002-7716-01*
Injection, necitumumab, 1mg
April 1, 2016
*Note that the product’s NDC code has been “zero‐filled” to ensure creation of an 11‐digit code that meets CMS standards.
The zero‐fill location is indicated in bold.
HCPCS=Healthcare Common Procedure Coding System; NDC=National Drug Code.
Portrazza was approved by the US Food and Drug Administration on November 24, 2015. Portrazza is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Portrazza is not indicated for the treatment of nonsquamous NSCLC.
Eli Lilly and Company announce the assignment of a product‐specific C‐code for Portrazza® (necitumumab) injection. The Centers for Medicare & Medicaid Services (CMS) released the April 2016 Update of the Hospital Outpatient Prospective Payment System (OPPS), which included designation of C9475 for Portrazza with the effective date of April 1, 2016.1
| Trade Name | HCPCS Code | Strength | NDC | CMS Long Descriptor | Effective Date |
| Portrazza | C9475 | 800 mg/50 mL (16 mg/mL) | 00002-7716-01* | Injection, necitumumab, 1mg | April 1, 2016 |
*Note that the product’s NDC code has been “zero‐filled” to ensure creation of an 11‐digit code that meets CMS standards.
The zero‐fill location is indicated in bold.
HCPCS=Healthcare Common Procedure Coding System; NDC=National Drug Code.
Portrazza was approved by the US Food and Drug Administration on November 24, 2015. Portrazza is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Portrazza is not indicated for the treatment of nonsquamous NSCLC.
No comments have been posted yet.